00:51 , Mar 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Hepatic

INDICATION: Non-alcoholic steatohepatitis (NASH) Patient sample, mouse and non-human primate (NHP) studies suggest CFLAR or its mimics could help treat NASH. In liver tissue samples, levels of CFLAR were lower in patients than in healthy volunteers,...
23:41 , Feb 21, 2017 |  BC Extra  |  Clinical News

Chinese scientists identify NASH target

Researchers in China identified CASP8 and FADD like apoptosis regulator (CFLAR; c-FLIP) as a new target for non-alcoholic steatohepatitis (NASH) that could suppress the disease and related metabolic disorders. The study was published in Nature...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Company News

Cardiff University, Tiziana Life Sciences deal

The university granted Tiziana exclusive, worldwide rights to small molecule OH14. Tiziana plans to develop the preclinical cellular FLICE-like inhibitory protein (c-FLIP) inhibitor for cancer. The company plans to start clinical testing of...
08:00 , Feb 2, 2004 |  BC Week In Review  |  Clinical News

AVI preclinical data

In a mouse model of transplant surgery, treatment with the c-FLIP inhibitor allowed the transplanted cells to survive. Data were presented at the Midwinter Conference of Immunologists in Pacific Grove. AVI BioPharma Inc. (AVII), Portland,...